Analyst Ratings for Pandion Therapeutics (PAND)
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
2/26/2021 | Leerink Partners | Geoffrey Porges | Downgrade | Market Perform (Outperform) |
60.00 (24.00) |
25.63 (60.05) |
134.3% | Details |
2/25/2021 | Morgan Stanley | Vikram Purohit | Downgrade | Equalweight (Overweight) |
N/A (N/A) |
25.63 (60.05) |
134.3% | Details |